Drug intelligence / Profile preview

GNR-069

Development stage: Phase 3
Lead developer: AO GENERIUM
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

GNR-069 is a biosimilar of romiplostim developed by GENERIUM Pharmaceuticals for the treatment of idiopathic thrombocytopenic purpura (ITP). It is a recombinant fusion protein that acts as an agonist of the thrombopoietin receptor, thereby stimulating platelet production. The drug has been evaluated in phase III clinical trials to compare its efficacy and safety with Nplate (the original romiplostim) in adult patients with ITP. The studies also assessed pharmacokinetics and immunogenicity. GNR-069 is administered subcutaneously and targets patients who have not responded adequately to first-line therapies or splenectomy[1][2][3][5][6][9].

Other names: Romiplostim biosimilar

Targets

TPOR (Thrombopoietin receptor)

Beyond the preview

Go deeper on GNR-069.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GNR-069.

Explore the full profile